Table 5.
The top 30 prominently enriched KEGG pathways for the 304 DMGs.
| KEGG ID | KEGG pathway | p-value | No. of DMG | DMG |
|---|---|---|---|---|
| hsa04071 | Sphingolipid signaling pathway | 9.08E−05 | 9 | GNA12/NFKB1/PPP2R5C/MAP3K5/SPTLC2/ROCK2/AKT3/MAPK14/PTEN |
| hsa05215 | Prostate cancer | 1.23E−04 | 8 | NFKB1/CREB1/TCF7L2/AKT3/FGFR2/PDGFD/PTEN/TCF7L1 |
| hsa04940 | Type I diabetes mellitus | 5.02E−04 | 5 | PTPRN2/HLA-DRB1/HLA-DQB1/HLA-C/HLA-DPB1 |
| hsa05166 | Human T-cell leukemia virus 1 infection | 5.76E−04 | 11 | NFKB1/ANAPC7/CREB1/SMAD4/AKT3/HLA-DRB1/PTEN/HLA-DQB1/HLA-C/TCF3/HLA-DPB1 |
| hsa04659 | Th17 cell differentiation | 1.33E−03 | 7 | NFKB1/RUNX1/SMAD4/MAPK14/HLA-DRB1/HLA-DQB1/HLA-DPB1 |
| hsa05145 | Toxoplasmosis | 1.74E−03 | 7 | NFKB1/AKT3/MAPK14/HLA-DRB1/HLA-DQB1/HLA-DPB1/GNAO1 |
| hsa05416 | Viral myocarditis | 2.31E−03 | 5 | ABL1/HLA-DRB1/HLA-DQB1/HLA-C/HLA-DPB1 |
| hsa04211 | Longevity regulating pathway | 2.54E−03 | 6 | NFKB1/SESN1/CAMKK2/CREB1/AKT3/RPTOR |
| hsa05330 | Allograft rejection | 2.73E−03 | 4 | HLA-DRB1/HLA-DQB1/HLA-C/HLA-DPB1 |
| hsa05321 | Inflammatory bowel disease | 3.28E−03 | 5 | NFKB1/IL18R1/HLA-DRB1/HLA-DQB1/HLA-DPB1 |
| hsa04151 | PI3K-Akt signaling pathway | 3.29E−03 | 13 | NFKB1/PPP2R5C/PHLPP1/CREB1/AKT3/MYB/IFNAR2/FGFR2/ITGA1/PDGFD/RPTOR/PTEN/TCL1A |
| hsa05221 | Acute myeloid leukemia | 3.51E−03 | 5 | NFKB1/RUNX1/TCF7L2/AKT3/TCF7L1 |
| hsa05332 | Graft-versus-host disease | 3.61E−03 | 4 | HLA-DRB1/HLA-DQB1/HLA-C/HLA-DPB1 |
| hsa05169 | Epstein–Barr virus infection | 3.99E−03 | 9 | NFKB1/USP7/AKT3/IFNAR2/MAPK14/HLA-DRB1/HLA-DQB1/HLA-C/HLA-DPB1 |
| hsa05164 | Influenza A | 4.88E−03 | 8 | NFKB1/RAE1/AKT3/IFNAR2/HLA-DRB1/TMPRSS4/HLA-DQB1/HLA-DPB1 |
| hsa05140 | Leishmaniasis | 6.41E−03 | 5 | NFKB1/MAPK14/HLA-DRB1/HLA-DQB1/HLA-DPB1 |
| hsa05220 | Chronic myeloid leukemia | 6.41E−03 | 5 | NFKB1/ABL1/RUNX1/SMAD4/AKT3 |
| hsa05152 | Tuberculosis | 6.63E−03 | 8 | NFKB1/CREB1/AKT3/CLEC7A/MAPK14/HLA-DRB1/HLA-DQB1/HLA-DPB1 |
| hsa04612 | Antigen processing and presentation | 6.78E−03 | 5 | CREB1/HLA-DRB1/HLA-DQB1/HLA-C/HLA-DPB1 |
| hsa04668 | TNF signaling pathway | 7.82E−03 | 6 | NFKB1/MAP3K5/IL18R1/CREB1/AKT3/MAPK14 |
| hsa05320 | Autoimmune thyroid disease | 9.05E−03 | 4 | HLA-DRB1/HLA-DQB1/HLA-C/HLA-DPB1 |
| hsa04152 | AMPK signaling pathway | 1.08E−02 | 6 | PPP2R5C/CAMKK2/CREB1/ACACA/AKT3/RPTOR |
| hsa05310 | Asthma | 1.20E−02 | 3 | HLA-DRB1/HLA-DQB1/HLA-DPB1 |
| hsa05213 | Endometrial cancer | 1.24E−02 | 4 | TCF7L2/AKT3/PTEN/TCF7L1 |
| hsa04611 | Platelet activation | 1.26E−02 | 6 | ROCK2/P2RY12/AKT3/PLA2G4A/MAPK14/P2RX1 |
| hsa05130 | Pathogenic Escherichia coli infection | 1.29E−02 | 8 | GNA12/NFKB1/ABL1/MYH10/ROCK2/BAIAP2/MAPK14/MYO10 |
| hsa04658 | Th1 and Th2 cell differentiation | 1.40E−02 | 5 | NFKB1/MAPK14/HLA-DRB1/HLA-DQB1/HLA-DPB1 |
| hsa04810 | Regulation of actin cytoskeleton | 1.77E−02 | 8 | GNA12/RDX/MYH10/ROCK2/BAIAP2/FGFR2/ITGA1/PDGFD |
| hsa05216 | Thyroid cancer | 1.94E−02 | 3 | TCF7L2/CCDC6/TCF7L1 |
| hsa05131 | Shigellosis | 2.01E−02 | 4 | NFKB1/ABL1/ROCK2/MAPK14 |
KEGG, Kyoto Encyclopedia of Genes and Genomes; DMG, differentially methylated gene; ID, identity.